3360-45-0

Usage

Uses

Used in Pharmaceutical Industry:
4-(Bromomethyl)-1-chloro-2-nitrobenzene is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to be chemically modified and incorporated into drug molecules, contributing to the development of new medications.
Used in Agrochemical Industry:
In the agrochemical industry, 4-(Bromomethyl)-1-chloro-2-nitrobenzene is used as a building block in the creation of agrochemicals, such as pesticides and herbicides, due to its potential to be transformed into active ingredients with specific pesticidal properties.
Used in Dye Industry:
4-(Bromomethyl)-1-chloro-2-nitrobenzene is utilized as a starting material in the production of dyes, where its chemical structure can be altered to produce a range of colorants for various applications, including textiles and plastics.
Used in Organic Compounds Manufacturing:
4-(BroMoMethyl)-1-chloro-2-nitrobenzene serves as a precursor in the manufacturing of other organic compounds, where its unique structure allows for the formation of a variety of chemical entities with different applications across various industries.
Used as a Reagent in Chemical Reactions:
4-(Bromomethyl)-1-chloro-2-nitrobenzene is employed as a reagent in various chemical reactions, facilitating specific transformations and syntheses, which are essential in the production of a wide array of chemical products.

Upstream product

• 89-60-1 1-chloro-4-methyl-2-nitro-benzene 
• 16588-34-4 4-chloro-3-nitro-benzaldehyde 

Downstream Products

• 4394-33-6 <4-Chlor-3-nitro-benzyl>-benzhydroxamat 
• 53271-21-9 4-benzyl-1-chloro-2-nitrobenzene 
• 122488-45-3 [9-(3-Amino-4-chloro-benzyl)-2-trifluoromethyl-9H-purin-6-yl]-dimethyl-amine 
• 122488-44-2 [9-(4-Chloro-3-nitro-benzyl)-2-trifluoromethyl-9H-purin-6-yl]-dimethyl-amine 
• 672883-57-7 (3S)-3-(3-cyclopentyloxy-4-methoxyphenylcarboxamido)-1-(4-chloro-3-nitrobenzyl)-2, 5-dioxoazolane 
• 169045-07-2 2-{[4-chloro-3-(methyloxy)phenyl]methyl}-1H-isoindole-1,3(2H)-dione 
• 180081-28-1 N-(4-chloro-3-nitrophenylmethyl)phthalimide 
• 219311-79-2 N-[5-(4,5-dihydro-1H-imidazol-2ylmethyl)-2-chloro-phenyl]-methanesulfonamide hydrochloride 
• 1192485-80-5 1-(4-chloro-3-nitrobenzyl)-1H-indole 
• 1330633-51-6 4-chloro-3-nitrobenzylthioacetic acid 
• 1330634-13-3 (E)-2',4',6'-trimethoxystyryl-4-chloro-3-nitrobenzylsulfone 
• 872404-53-0 4-chloro-3-nitrobenzylsulfonylacetic acid 
• 1330633-75-4 (E)-2',4',6'-trimethoxystyryl-4-chloro-3-aminobenzylsulfone 
• 51250-90-9 2-(4-chloro-3-nitrophenyl)acetonitrile 

Relevant academic research and scientific papers

Water bridges are essential to neonicotinoids: Insights from synthesis, bioassay and molecular modelling studies

Water-bridged H-bonds have been observed in many cases of ligand-receptor recognitions. To explore the roles of water bridges in the binding of neonicotinoids with receptors, twenty-four neonicotinoid compounds with nine fragments, including 1H-1,2,3-tria

Discovery of novel quinazoline-2,4(1H,3H)-dione derivatives as potent PARP-2 selective inhibitors

The PARP-2 selective inhibitor is important for clarifying specific roles of PARP-2 in the pathophysiological process and developing desired drugs with reduced off-target side effects. In this work, a series of novel quinazoline-2,4(1H,3H)-dione derivatives was designed and synthesized to explore isoform selective PARP inhibitors. As a result, compound 11a (PARP-1 IC50?=?467?nM, PARP-2 IC50?=?11.5?nM, selectivity PARP-1/PARP-2?=?40.6) was disclosed as the most selective PARP-2 inhibitor with high potency to date. The binding features of compound 11a within PARP-1 and PARP-2 were investigated respectively to provide useful insights for the further construction of new isoform selective inhibitors of PARP-1 and PARP-2 by using CDOCKER program.

Structural Determinants of the Selectivity of 3-Benzyluracil-1-acetic Acids toward Human Enzymes Aldose Reductase and AKR1B10

The human enzymes aldose reductase (AR) and AKR1B10 have been thoroughly explored in terms of their roles in diabetes, inflammatory disorders, and cancer. In this study we identified two new lead compounds, 2-(3-(4-chloro-3-nitrobenzyl)-2,4-dioxo-3,4-dihy

Discovery of a clinical stage multi-kinase inhibitor sodium (E)-2-{2-methoxy-5-[(2′,4′,6′-trimethoxystyrylsulfonyl)methyl] phenylamino}acetate (ON 01910.Na): Synthesis, structure-activity relationship, and biological activity

Cyclin D proteins are elevated in many cancer cells, and targeted deletion of cyclin D1 gene in the mammary tissues protects mice from breast cancer. Accordingly, there is an increasing awareness of this novel nonenzymatic target for cancer therapeutics. We have developed novel, nonalkylating styrylbenzylsulfones that induce cell death in wide variety of cancer cells without affecting the proliferation and survival of normal cells. The development of derivatized styrylbenzylsulfones followed logically from a tumor cell cytotoxicity screen performed in our laboratory that did not have an a priori target profile. Modifications of some of the precursor molecules led to lead optimization with regard to tumor cell cytotoxicity. In this report we describe the synthesis and structure-activity relationships of novel, nonalkylating (E)-styrylbenzylsulfones and the development of the novel anticancer agent sodium (E)-2-{2-methoxy-5-[(2′,4′,6′- trimethoxystyrylsulfonyl)methyl]phenylamino}acetate (ON 01910.Na), which is in phase III trials for myelodysplastic syndromes (MDS) associated with aberrant expression of cyclin D proteins.

A new efficient synthetic method for 3-iodothyronamine and its potent hypothermic efficacy

We developed a new efficient synthetic method for a 3-iodothyronamine (T1AM) that has advantages of less synthetic steps and much higher overall yield compared to those in the conventional method. Our animal study showed that T1AM synthesized by the method exerted a potent hypothermic effect in non-hibernator mice.

Indole derivatives as MCP-1 receptor antagonists

A compound of Formula I, wherein: R1 is hydrogen, halo, methyl, ethyl or methoxy; R2 is hydrogen, halo, methyl, ethyl or methoxy; R3 is a halo group, lower alkyl, lower alkenyl, lower alkynyl, alkoxy, trifluoromethyl, nitro, cyano, trifluoromethoxy, C(O)R7, or S(O)nR7 where n is 0, 1 or 2 and R7 is an alkyl group; R4 is a halo, trifluoromethyl, methylthio, methoxy, trifluoromethoxy or lower alkyl, lower alkenyl or lower alkynyl or COR8 where R8 is lower alkyl; R6 is hydrogen, halo, lower alkyl, lower alkenyl, lower alkynyl or COR9 where R9 is lower alkyl; provided that when R1 is hydrogen, halo or methoxy, R2 is hydrogen, halo, methyl, ethyl or methoxy, R5 and R6 are both hydrogen, and one of R3 or R4 is not halo or trifluoromethyl; or a pharmaceutically acceptable salt or prodrug thereof. These compounds have useful activity for the treatment of inflammatory disease, specifically in antagonizing an MCP-1 mediated effect in a warm-blooded animal such as a human being.

Anthranilic acid derivatives as inhibitors of the cGMP-phosphodiesterase

Compounds of formula (I) STR1where R 1 is hydrogen; R 2 is nitro, cyano or halo(lower)alkyl; R 3 is phenyl substituted with one or more substituents selected from halogen, cyano and lower alkoxy; A is a lower alkylene group; R 4 is a group CR 6 R 7 R 8 wherein R 6 and R 7 form, together with the carbon atom to which they are attached a cycloalkyl group optionally substituted with hydroxy, lower alkoxy or a lower alkanoylamino; and R 8 is hydrogen; its prodrug and a salt thereof.

Highly selective aldose reductase inhibitors. II. Optimization of the aryl part of 3-(arylmethyl)-2,4,5-trioxoimidazolidine-1-acetic acids

Accumulation of intracellular sorbitol, the product of glucose reduction catalyzed by aldose reductase (AR) [EC 1.1.1.21], is thought to be the main culprit in the development of diabetic complications. A series of 3- arylalkyl-2,4,5-trioxoimidazolidine-1-acetic acids was prepared and tested for inhibitory activities towards AR and aldehyde reductase (ALR) [EC 1.1.1.2]. These derivatives showed strong inhibitory activity against AR without markedly inhibiting ALR. In particular, the compounds with 3- nitrophenyl, 4-chloro-3-nitrophenyl, and chloro-substituted benzothiazolyl groups as the aryl part showed powerful AR-inhibitory activity. The chloro- substituted benzothiazolyl compound showed an AR selectivity of more than 5000 fold.